Biogen Idec will purchase all rights to the blockbuster multiple sclerosis drug Tysabri from its partner, Elan Pharmaceuticals, for $3.25 billion, adding a capstone to a long and tangled journey for a drug that was once withdrawn from the market.
Biogen Idec will purchase all rights to the blockbuster multiple sclerosis drug Tysabri from its partner, Elan Pharmaceuticals, for $3.25 billion, adding a capstone to a long and tangled journey for a drug that was once withdrawn from the market.